secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-09-09T23:59:59+00:00
Accession:  0001493152-22-025445
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q4 net loss $0.10/share; cash $14.5M; positive Phase 2 data for ANEB-001
--------------------------------------------------------------------------------

- Q4 fiscal 2022 net loss of $2.3M ($0.10 per share), vs $29.1M ($1.59) in prior year quarter.
- Operating expenses Q4 $2.3M; fiscal year $6.8M; cash burn Q4 $2.0M; cash at June 30 $14.5M.
- Positive Phase 2 Part A topline: ANEB-001 significantly reduced VAS feeling high (p<0.0001) and improved alertness (p<0.01).
- Plan to initiate Part B evaluating lower doses by end of Q3 2022; IND submission for U.S. trials by end of 2022.
- Inaugural R&D Day scheduled for September 26, 2022 in New York City; Part B data to be presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222025445/0001493152-22-025445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222025445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-025445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer